

PRESCRIBING INFORMATION

OVRAL® 21

Norgestrel and Ethinyl Estradiol Tablets USP

250 µg of d-norgestrel supplied as 500 µg norgestrel (dl-racemate) and 50 µg ethinyl estradiol

ORAL CONTRACEPTIVE

© WYETH CANADA  
MONTREAL, CANADA

DATE OF REVISION:  
January 14, 2009

**Submission Control Number: 125078**

THIS PRESCRIBING INFORMATION IS THE EXCLUSIVE PROPERTY OF WYETH CANADA AND CANNOT BE REFERENCED, PUBLISHED OR COPIED WITHOUT THE WRITTEN APPROVAL OF WYETH CANADA.

OVRAL® 21  
(Norgestrel and Ethinyl Estradiol Tablets USP)

COMPLETE PRESCRIBING INFORMATION  
TABLE OF CONTENTS

	PAGE
NAME .....	1
THERAPEUTIC CLASSIFICATION .....	1
ACTION .....	1
INDICATION .....	1
CONTRAINDICATIONS .....	2
WARNINGS .....	3
PRECAUTIONS .....	6
NON-CONTRACEPTIVE BENEFITS OF ORAL CONTRACEPTIVES .....	23
ADVERSE REACTIONS .....	24
SYMPTOMS AND TREATMENT OF ACUTE OVERDOSAGE .....	29
DOSAGE AND ADMINISTRATION .....	29
SPECIAL NOTES ON ADMINISTRATION .....	30
PHARMACEUTICAL INFORMATION .....	35
AVAILABILITY OF DOSAGE FORMS .....	37
INFORMATION FOR THE CONSUMER .....	38
A. Information To Patients On How To Take The Birth Control Pill .....	38
B. Package Insert .....	46
C. Supplementary Information Booklet .....	59
CLINICAL TRIALS .....	81
PHARMACOLOGY .....	90
TOXICOLOGY .....	94
REFERENCES (1-15) .....	101

**NAME OF DRUG**

OVRAL® 21

(Norgestrel and Ethinyl Estradiol Tablets USP)

**THERAPEUTIC CLASSIFICATION**

ORAL CONTRACEPTIVE

**ACTION**

Although the primary mechanism of action is inhibition of ovulation, the effectiveness of OVRAL® 21 tablets (OVRAL®) may also result from other mechanisms of action, such as hostility of the cervical mucus to sperm penetration and migration.

**INDICATION**

OVRAL® tablets are indicated for conception control in circumstances where low dosage estrogen formulations prove to be unacceptable.

OVRAL® tablets are not indicated for post-coital interception even though the formulation has been advocated in clinical publications.
--

## CONTRAINDICATIONS

Combination Oral Contraceptives (COCs) are contraindicated in the following:

1. History of or actual thrombophlebitis or thromboembolic disorders.
2. History of or actual cerebrovascular disorders.
3. History of or actual myocardial infarction or coronary arterial disease.
4. Deep vein thrombosis (current or history).
5. Thrombogenic valvulopathies and Thrombogenic rhythm disorders.
6. Hereditary or acquired thrombophilias.
7. Migraine with focal neurological symptoms, such as aura (current or history).
8. Active liver disease, or history of or actual benign or malignant liver tumours.
9. Known or suspected carcinoma of the breast.
10. Known or suspected estrogen-dependent neoplasia.
11. Undiagnosed abnormal vaginal bleeding.
12. Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields.
13. When pregnancy is suspected or diagnosed.
14. Hypersensitivity to any of the components of OVRAL® .
15. Diabetes with vascular involvement
16. Uncontrolled hypertension

## WARNINGS

### 1. **Predisposing Factors for Coronary Artery Disease**

Cigarette smoking increases the risk of serious cardiovascular side effects and mortality from COC use. This risk increases with age and with the extent of smoking. Convincing data are available to support an upper age limit of 35 years for oral contraceptive use in women who smoke.

Other women who are independently at high risk for cardiovascular disease include those with diabetes, hypertension, abnormal lipid profile, or a family history of these. Whether COCs accentuate this risk is unclear.

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels. This risk increases with age and becomes significant in COC-users older than 35 years of age. Women should be counselled not to smoke.

### 2. **Discontinue Medication at the Earliest Manifestation of the following:**

- A. Venous and arterial thrombosis and thromboembolism

Use of COCs is associated with an increased risk of venous and arterial thrombotic and thromboembolic events. Some epidemiological studies suggest that COCs with 50 µg or more

ethinylestradiol may be associated with a higher risk of such events than COCs with a lower dose of ethinylestradiol. For any particular estrogen/progestin combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestin that is compatible with a low failure rate and the needs of the individual patient.

New users of COCs should be started on preparations containing less than 50 µg of estrogen.

- Venous thrombosis and thromboembolism

Use of COCs increases the risk of venous thrombotic and thromboembolic events. Reported events include deep venous thrombosis, thrombophlebitis, pulmonary embolism, and mesenteric thrombosis. For information on retinal vascular thrombosis see **PRECAUTIONS** (Ocular Disease). The use of any COCs carries an increased risk of venous thrombotic and thromboembolic events compared with no use. The excess risk is highest during the first year a woman ever uses a combined oral contraceptive. This increased risk is less than the risk of venous thrombotic and thromboembolic events associated with pregnancy which is estimated as 60 cases per 100,000 woman-years. Venous thromboembolism is fatal in 1-2% of cases.

The risk of venous thrombotic and thromboembolic events is further increased in women with conditions predisposing for venous thrombosis and thromboembolism.

Caution must be exercised when prescribing COCs for such women.

- Arterial thrombosis and thromboembolism

The use of COCs increases the risk of arterial thrombotic and thromboembolic events. Reported events

include myocardial infarction and cerebrovascular events (ischemic and hemorrhagic stroke, transient ischemic attack). For information on retinal vascular thrombosis see **PRECAUTIONS (Ocular Disease)**.

The risk of arterial thrombotic and thromboembolic event is further increased in women with underlying risk factors. Caution must be exercised when prescribing COCs for women with risk factors for arterial thrombotic and thromboembolic events.

B. Conditions which Predispose to Venous Thrombosis and to Thromboembolism (e.g. obesity, surgery or trauma with increased risk of thrombosis, immobilization after accidents or confinement to bed during long-term illness, recent delivery or second-trimester abortion [see Special Notes on Administration]). Other nonhormonal methods of contraception should be used until regular activities are resumed. For use of oral contraceptives when surgery is contemplated, see **PRECAUTIONS**.

Examples of risk factors for arterial thrombotic and thromboembolic events are smoking, hypertension, hyperlipidemias, obesity and increasing age.

C. Visual Defects, Partial or Complete

D. Papilledema, or Ophthalmic Vascular Lesions

E. Severe Headache of Unknown Etiology, Worsening of Pre-existing Migraine or

Development of New Migraine. (particularly migraine with aura). Women with migraine who take COCs may be at increased risk of stroke.

3. A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR=1.24) of having breast cancer diagnosed in women who are currently using COCs compared to never-users. The increased risk gradually disappears during the course of the 10 years after cessation of COC use. These studies do not provide evidence for causation. The observed pattern of increased risk of breast cancer diagnosis may be due to an earlier detection of breast cancer in COCs users (due to more regular clinical monitoring), the biological effects of COCs or a combination of both. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the lifetime risk of breast cancer. Breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users.

## **PRECAUTIONS**

### **1. Physical Examination and Follow-up**

Before oral contraceptives are used, a thorough history and physical examination should be performed, including a blood pressure determination. Breasts, liver, extremities and pelvic organs should be examined and a Papanicolaou smear should be taken if the patient has been sexually active.

The first follow-up visit should be three months after oral contraceptives are prescribed. Thereafter, examinations should be performed at least once a year or more frequently if indicated.

At each annual visit, examination should include those procedures that were done at the initial visit as outlined above or per recommendations of the Canadian Workshop on Screening for Cancer of the Cervix. Their suggestion was that, for women who had two consecutive negative Pap smears, screening could be continued every three years to the age of 69.

## 2. **Pregnancy**

Oral contraceptives should not be taken by pregnant women. However, if conception accidentally occurs while taking the pill, there is no conclusive evidence that the estrogen and progestin contained in the oral contraceptive will damage the developing child.

## 3. **Breast-feeding**

In breast-feeding women, the use of COCs results in the hormonal components being excreted in breast milk and may reduce its quantity and quality. Some adverse effects on the child have been reported, including jaundice and breast enlargement.

The use of COCs is generally not recommended until the nursing mother has completely weaned her child.

## 4. **Hepatic Function**

Patients who have had jaundice, including a history of cholestatic jaundice during pregnancy or a history of COC-related cholestasis, are more likely to have this condition with COC use and, they should be given COCs with great care and under close observation. If these patients receive a COC they should be carefully monitored and, if the condition recurs, the COC should be

discontinued.

The development of severe generalized pruritus or icterus requires that the medication be withdrawn until the problem is resolved.

If a patient develops jaundice that proves to be cholestatic in type, the use of oral contraceptives should not be resumed. In patients taking oral contraceptives, changes in the composition of the bile may occur and an increased incidence of gallstones has been reported.

Hepatic nodules (adenomas and focal nodular hyperplasia) have been reported, particularly in long-term users of COCs. Although these lesions are extremely rare, they have caused fatal intra-abdominal hemorrhage and should be considered in women with an abdominal mass, acute abdominal pain, or evidence of intra-abdominal bleeding.

Hepatocellular carcinoma may be associated with COC use. The risk appears to increase with duration of COC use. However, the attributable risk (the excess incidence) of liver cancer in OC users is extremely small.

Hepatocellular injury has been reported with COC use. Early identification of drug-related hepatocellular injury can decrease the severity of hepatotoxicity when the drug is discontinued. If hepatocellular injury is diagnosed, patients should stop their COC, use a non-hormonal form of contraception and consult their doctor.

## 5. **Hypertension**

Patients with essential hypertension whose blood pressure is well-controlled may be given oral contraceptives but only under close supervision. If a significant elevation of blood pressure in previously normotensive or hypertensive subjects occurs at any time during the administration of the drug, cessation of medication is necessary.

Increases in blood pressure have been reported in women taking COCs. Elevated blood pressure associated with oral contraceptive use will generally return to baseline after stopping oral contraceptives, and there appears to be no difference in the occurrence of hypertension among ever- and never-users.

## 6. **Diabetes**

Glucose intolerance has been reported in COC users. Current low-dose COCs exert minimal impact on glucose metabolism. Diabetic patients, or those with a family history of diabetes, should be observed closely to detect any worsening of carbohydrate metabolism. Women who are predisposed to diabetes, with impaired glucose tolerance or who have diabetes mellitus should be carefully monitored if using COCs. Young diabetic patients whose disease is of recent origin, well-controlled, and not associated with hypertension or other signs of vascular disease such as ocular fundal changes, should be monitored more frequently while using oral contraceptives.

## 7. **Lipid Effects**

A small proportion of women will have adverse lipid changes while taking oral contraceptives. Nonhormonal contraception should be considered in women with uncontrolled dyslipidemias.

Persistent hypertriglyceridemia may occur in a small proportion of oral contraceptives users.

Elevations of plasma triglycerides may lead to pancreatitis and other complications.

Women who are being treated for hyperlipidemias should be followed closely if they elect to use oral contraceptives.

#### 8. **Ocular Disease**

Patients who are pregnant or are taking oral contraceptives, may experience corneal edema that may cause visual disturbances and changes in tolerance to contact lenses, especially of the rigid type. Soft contact lenses usually do not cause disturbances. If visual changes or alterations in tolerance to contact lenses occur, temporary or permanent cessation of wear may be advised.

With use of COCs, there have been reports of retinal vascular thrombosis which may lead to partial or complete loss of vision. If there are signs or symptoms such as visual changes, onset of proptosis or diplopia, papilledema, or retinal vascular lesions, the COC should be discontinued and the cause immediately evaluated.

#### 9. **Breasts**

Increasing age and a strong family history are the most significant risk factors for the development of breast cancer. Other established risk factors include obesity, nulliparity and late age at first full-term pregnancy. The identified groups of women that may be at increased risk

of developing breast cancer before menopause are long-term users of oral contraceptives (more than eight years) and starters at early age. In a few women, the use of oral contraceptives may accelerate the growth of an existing but undiagnosed breast cancer. Since any potential increased risk related to oral contraceptive use is small, there is no reason to change prescribing habits at present (see WARNINGS).

Women receiving oral contraceptives should be instructed in self-examination of their breasts. Their physicians should be notified whenever any masses are detected. A yearly clinical breast examination is also recommended because, if a breast cancer should develop, drugs that contain estrogen may cause a rapid progression.

#### 10. **Cervix**

Some studies suggest that COC use may be associated with an increase in the risk of cervical intraepithelial neoplasia or invasive cervical cancer in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. In cases of undiagnosed abnormal genital bleeding, adequate diagnostic measures are indicated.

#### 11. **Fibroids**

Patients with fibroids (leiomyomata) should be carefully observed. Sudden enlargement, pain, or tenderness require discontinuation of the use of COCs.

## 12. Emotional Disorders

Patients with a history of emotional disturbances, especially the depressive type, may be more prone to have a recurrence of depression while taking oral contraceptives. In cases of a serious recurrence, a trial of an alternate method of contraception should be made, which may help to clarify the possible relationship. Women with premenstrual syndrome (PMS) may have a varied response to oral contraceptives, ranging from symptomatic improvement to worsening of the condition.

## 13. Laboratory Tests

Results of laboratory tests should be interpreted in the light that the patient is on COCs. The following laboratory tests are modified.

### Liver Function Tests

Bromsulphthalein Retention Test (BSP)	Moderate increase
AST (SGOT) and GGT	Minor increase
Alkaline Phosphatase	Variable increase
Serum Bilirubin	Increased, particularly in conditions predisposing to or associated with hyperbilirubinemia

Coagulation Tests

Factors II, VII, IX, X, XII and XIII	Increased
Factor VIII	Mild increase
Platelet aggregation and adhesiveness	Mild increase in response to common aggregating agents
Fibrinogen	Increased
Plasminogen	Mild increase
Antithrombin III	Mild increase
Prothrombin Time	Increased

Thyroid Function Tests

Protein-bound Iodine (PBI)	Increased
Total Serum Thyroxine (T <sub>3</sub> and T <sub>4</sub> )	Increased
Thyroid Stimulating Hormone (TSH)	Unchanged
Free T3 Resin Uptake	Decreased

Adrenocortical Function Tests

Plasma Cortisol	Increased
Cortisol Binding Globulin	Increased

Dehydroepiandrosterone sulfate (DHEAS)	Decreased
--	-----------

Renal Function

Plasma Creatinine	Increased
-------------------	-----------

Creatinine Clearance	Increased
----------------------	-----------

Miscellaneous Tests

Serum Folate	Occasionally decreased
--------------	------------------------

Glucose Tolerance Test	Variable increase with return to normal after 6 to 12 months
------------------------	--

Insulin Response	Mild to moderate increase
------------------	---------------------------

c-Peptide Response	Mild to moderate increase
--------------------	---------------------------

14. **Tissue Specimens**

Pathologists should be advised of oral contraceptive therapy when specimens obtained from surgical procedures and Pap smears are submitted for examination.

**15. Return to Fertility**

After discontinuing oral contraceptive therapy, the patient should delay pregnancy until at least one normal spontaneous cycle has occurred in order to date the pregnancy. An alternate contraceptive method should be used during this time.

**16. Vaginal Bleeding**

In some women withdrawal bleeding may not occur during the tablet-free interval. If the COC has not been taken according to directions prior to the first missed withdrawal bleed, or if two consecutive withdrawal bleeds are missed, tablet-taking should be discontinued and a nonhormonal back-up method of contraception should be used until the possibility of pregnancy is excluded.

Breakthrough bleeding/spotting may occur in women taking COC, especially during the first three months of use. If this bleeding persists or recurs, nonhormonal causes should be considered and adequate diagnostic measures may be indicated to rule out pregnancy, infection, malignancy, or other conditions. Persistent irregular vaginal bleeding requires assessment to exclude underlying pathology. If pathology has been excluded (see also PRECAUTIONS: Cervix), continued use of the COC or a change to another formulation may solve the problem.

**17. Amenorrhea**

Women having a history of oligomenorrhea, secondary amenorrhea, or irregular cycles may remain anovulatory or become amenorrheic following discontinuation of estrogen-progestin combination therapy.

Amenorrhea, especially if associated with breast secretion, that continues for six months or more after withdrawal, warrants a careful assessment of hypothalamic-pituitary function.

**18. Other**

Patients should be counseled that this product does not protect against HIV infection (AIDS) or other sexually transmitted diseases.

Diarrhea and/or vomiting may reduce hormone absorption resulting in decreased serum concentrations.

**19. Thromboembolic complications - Post-surgery**

There is an increased risk of post-surgery thromboembolic complications in COC users after major surgery. If feasible, COC should be discontinued and an alternative method substituted at least one month prior to **major** elective surgery and during periods of prolonged immobilization. COCs should not be resumed for at least two weeks after major elective surgery, and only after the first menstrual period has occurred following hospital discharge.

## 20. **Drug Interactions**

The concurrent administration of oral contraceptives with other substances may result in an altered response to either agent. Decreased ethinyl estradiol (EE) serum concentration may cause an increased incidence of breakthrough bleeding and menstrual irregularities and may possibly reduce efficacy of the oral contraceptive.

During concomitant use of EE containing products and substances that may lead to decreased EE serum concentration, it is recommended that a nonhormonal back-up method of birth control (such as condoms and spermicide) be used in addition to the regular intake of OVRAL. In the case of prolonged use of such substances oral contraceptives should not be considered the primary contraceptive.

After discontinuation of substances that may lead to decreased EE serum concentrations, use of a nonhormonal back-up method is recommended for at least 7 days. Longer use of a back-up method is advisable after discontinuation of substances that have lead to induction of hepatic microsomal enzymes, resulting in decreased EE serum concentrations. It may sometimes take several weeks until enzyme induction has completely subsided, depending on dosage, duration of use and rate of elimination of the inducing substance.

Reduced effectiveness of the oral contraceptive, should it occur, is more likely with the low-dose formulations. It is important to ascertain all drugs that a patient is taking, both prescription and non-prescription, before oral contraceptives are prescribed.

**Examples of substances that may decrease serum EE concentrations:**

- Any substance that reduces gastrointestinal transit time
- Hypericum perforatum, also known as St. John's wort, and ritonavir (possibly by induction of hepatic microsomal enzymes).
- Substances that induce hepatic microsomal enzymes, such as rifampicin, rifabutin, barbiturates, primidone, phenylbutazone, phenytoin, dexamethasone, griseofulvin, modafinil, some protease inhibitors, topiramate.
- Certain antibiotics (eg, ampicillin and other penicillins, tetracyclines), by a decrease of enterohepatic circulation of estrogens.

**Examples of substances that may increase serum EE concentrations:**

- atorvastatin
- Competitive inhibitors for sulfation in the gastrointestinal wall, such as ascorbic acid (vitamin C) and acetaminophen.
- Substances that inhibit cytochrome P 450 3A4 isoenzymes such as indinavir, fluconazole, and troleandomycin.

Troleandomycin may increase the risk of intrahepatic cholestasis during coadministration with COCs.

Ethinyl estradiol may interfere with the metabolism of other drugs by inhibiting hepatic microsomal enzymes, or by inducing hepatic drug conjugation, particularly glucuronidation.

Accordingly, plasma and tissue concentrations of some drugs may either be increased (eg. cyclosporine, theophylline, corticosteroids) or decreased (eg. lamotrigine).

In patients treated with flunarizine, use of oral contraceptives has been reported to increase the risk of galactorrhea.

The prescribing information of concomitant medications should be consulted to identify potential interactions.

For possible drug interactions with OCs see Tables I and II.

TABLE I\*  
Drugs that May Decrease the Efficacy of Oral Contraceptives

	Drug	Proposed Mechanism	Suggested Management
Anticonvulsants	Carbamazepine Ethosuximide Phenobarbital Phenytoin Primidone	Induction of hepatic microsomal enzymes. Rapid metabolism of estrogen and increased binding of progestin and ethinyl estradiol to SHBG.	Use higher dose OCs (50 µg ethinyl estradiol), another drug or another method.
Antibiotics	Ampicillin Cotrimoxazole Penicillin	Enterohepatic circulation disturbance, intestinal hurry.	For short course, use additional method or use another drug. For long course, use another method.
	Rifampin	Increased metabolism of progestins. Suspected acceleration of estrogen metabolism.	Use another method.
	Chloramphenicol Metronidazole Neomycin Nitrofurantoin Sulfonamides Tetracyclines	Induction of hepatic microsomal enzymes. Also disturbance of enterohepatic circulation.	For short course, use additional method or use another drug. For long course, use another method.
	Troleandomycin	May retard metabolism of OCs, increasing the risk of cholestatic jaundice.	
Antifungals	Griseofulvin	Stimulation of hepatic metabolism of contraceptive steroids may occur.	Use another method.
Cholesterol Lowering Agents	Clofibrate	Reduces elevated serum triglycerides and cholesterol; this reduces OC efficacy.	Use another method.
Sedatives and Hypnotics	Benzodiazepines Barbiturates Chloral Hydrate Glutethimide Meprobamate	Induction of hepatic microsomal enzymes.	For short course, use additional method or another drug. For long course, use another method or higher dose OCs.
Antacids		Decreased intestinal absorption of progestins.	Dose two hours apart.
Other Drugs	Phenylbutazone** Antihistamines** Analgesics** Antimigraine Preparations** Vitamin E	Reduced OC efficacy has been reported. Remains to be confirmed.	

\* Adapted from Dickey, RP, ed.: *Managing Contraceptive Pill Patients*, 5th edition Creative Informatics Inc., Durant, OK, 1987.

\*\* Refer to *Oral Contraceptives 1994*, A Report by the Special Advisory Committee on Reproductive physiology to the Drugs Directorate, Health Protection Branch, Health Canada.

TABLE II\*

## Modification of Other Drug Action by Oral Contraceptives

Class of Compound	Drug	Modification of Drug Action	Suggested Management
Alcohol		Possible increased levels of ethanol or acetaldehyde.	Use with caution.
Alpha-II Adrenoreceptor Agents	Clonidine	Sedation effect increased.	Use with caution.
Anticoagulants	All	OCs increase clotting factors, decrease efficacy. However, OCs may potentiate action in some patients.	Use another method.
Anticonvulsants	All	Fluid retention may increase risk of seizures.	Use another method.
Antidiabetic Drugs	Oral Hypoglycemics and Insulin	OCs may impair glucose tolerance and increase blood glucose.	Use low-dose estrogen and progestin OC or another method. Monitor blood glucose.
Antihypertensive Agents	Guanethidine and Methyldopa	Estrogen component causes sodium retention, progestin has no effect.	Use low-dose estrogen OC or use another method.
	Beta Blockers	Increased drug effect (decreased metabolism)	Adjust dose of drug if necessary. Monitor cardiovascular status.
Antipyretics	Acetaminophen	Increased metabolism and renal clearance.	Dose of drug may have to be increased.
	Antipyrine	Impaired metabolism.	Decrease dose of drug.
	ASA	Effects of ASA may be decreased by the short-term use of OCs.	Patients on chronic ASA therapy may require an increase in ASA dosage.
Aminocaproic Acid		Theoretically, a hypercoagulable state may occur because OCs augment clotting factors.	Avoid concomitant use.
Betamimetic Agents	Isoproterenol	Estrogen causes decreased response to these drugs.	Adjust dose of drug as necessary. Discontinuing OCs can result in excessive drug activity.
Caffeine		The actions of caffeine may be enhanced as OCs may impair the hepatic metabolism of caffeine.	Use with caution.

TABLE II (continued)\*  
Modification of Other Drug Action by Oral Contraceptives

Class of Compound	Drug	Modification of Drug Action	Suggested Management
Cholesterol Lowering Agents	Clofibrate	Their action may be antagonized by OCs. OCs may also increase metabolism of clofibrate.	May need to increase dose of clofibrate.
Corticosteroids	Prednisone	Markedly increased serum levels.	Possible need for decrease in dose.
Cyclosporine		May lead to an increase in cyclosporine levels and hepatotoxicity.	Monitor hepatic function. The cyclosporine dose may have to be decreased.
Folic Acid		OCs have been reported to impair folate metabolism.	May need to increase dietary intake, or supplement.
Meperidine		Possible increased analgesia and CNS depression due to decreased metabolism of meperidine.	Use combination with caution.
Phenothiazine Tranquilizers	All Phenothiazines, Reserpine and similar drugs	Estrogen potentiates the hyperprolactinemia effect of these drugs.	Use other drugs or lower dose OCs. If galactorrhea or hyperprolactinemia occurs, use other method.
Sedatives and Hypnotics	Chlordiazepoxide Lorazepam Oxazepam Diazepam	Increased effect (increased metabolism)	Use with caution.
Theophylline	All	Decreased oxidation, leading to possible toxicity.	Use with caution. Monitor theophylline levels.
Tricyclic Antidepressants	Clomipramine (possibly others)	Increased side effects: i.e., depression.	Use with caution.
Vitamin B <sub>12</sub>		OCs have been reported to reduce serum levels of Vitamin B <sub>12</sub> .	May need to increase dietary intake, or supplement.

\* Adapted from Dickey, R.P., ed.: *Managing Contraceptive Pill Patients*, 5th edition Creative Informatics Inc., Durant, OK, 1987.

## NON-CONTRACEPTIVE BENEFITS OF ORAL CONTRACEPTIVES

Several health advantages other than contraception have been reported.

- Combination oral contraceptives reduce the incidence of cancer of the endometrium and ovaries.
- Oral contraceptives reduce the likelihood of developing benign breast disease.
- Oral contraceptives reduce the likelihood of development of functional ovarian cysts.
- Pill users have less menstrual blood loss and have more regular cycles, thereby reducing the chance of developing iron-deficiency anemia.
- The use of oral contraceptives may decrease the severity of dysmenorrhea and premenstrual syndrome, and may improve acne vulgaris, hirsutism, and other androgen-mediated disorders.
- Other non-contraceptive benefits are outlined in Oral Contraceptives 1994, Health Canada.

Oral contraceptives **do not protect** against sexually transmitted diseases including HIV/AIDS. For protection against STDs, it is advisable to use latex condoms **in combination with** oral contraceptives.

## ADVERSE REACTIONS

An increased risk of the following serious adverse reactions has been associated with the use of combination oral contraceptives:

- Thrombophlebitis
- Pulmonary embolism
- Mesenteric thrombosis
- Neuro-ocular lesions (e.g. retinal thrombosis)
- Myocardial infarction
- Cerebral thrombosis
- Cerebral hemorrhage
- Hypertension
- Benign hepatic tumours (eg. focal nodular hyperplasia, hepatic adenomas)
- Gallbladder disease, including gallstones\*
- Stroke
- Transient ischemic attack
- Venous thrombosis
- Cervical intraepithelial neoplasia
- Cervical cancer
- Being diagnosed with breast cancer

\* OCs may worsen existing gallbladder disease and may accelerate the development of this disease in previously asymptomatic women.

The following adverse reactions also have been reported in patients receiving oral contraceptives:

Nausea and vomiting, usually the most common adverse reaction, occurs in approximately 10 percent or fewer of patients during the first cycle. Other reactions, as a general rule, are seen less frequently or only occasionally.

#### **Other Adverse Reactions:**

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed drug related:

- Gastrointestinal symptoms (such as abdominal pain, cramps and bloating)
- Breakthrough bleeding
- Spotting
- Change in menstrual flow
- Amenorrhea
- Dysmenorrhea
- Temporary infertility after discontinuation of treatment
- Fluid retention/Edema

- Melasma which may persist
- Breast pain: tenderness, enlargement, secretion
- Change in weight (increase or decrease)
- Change in cervical erosion and secretion
- Diminution in lactation when given immediately postpartum
- Cholestatic jaundice
- Headache, including migraines
- Rash (allergic)
- chloasma (melasma), which may persist
- Mood changes, including depression
- Reduced tolerance to carbohydrates
- Vaginitis including candidiasis
- Change in corneal curvature (steepening)
- intolerance to contact lenses
- Retinal vascular thrombosis
- Hepatocellular injury (e.g. hepatitis, hepatic function abnormal)

The following adverse reactions have been reported in users of oral contraceptives, and the association has been neither confirmed nor refuted:

- Congenital anomalies

- Premenstrual syndrome
- Cataracts
- Optic neuritis\*\*
- Changes in appetite (increase or decrease)
- Cystitis-like syndrome
- Nervousness
- Dizziness
- Hirsutism
- Loss of scalp hair
- Erythema multiform
- Erythema nodosum
- Hemorrhagic eruption
- Exacerbation of porphyria
- Impaired renal function
- Hemolytic uremic syndrome
- Budd-Chiari syndrome
- Acne
  
- Changes in libido

- Colitis
- Sickle-cell disease
- Cerebral-vascular disease with mitral valve prolapse
- Lupus-like syndromes
- Anaphylactic (anaphylactoid reactions, including very rare cases of urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms)
- Exacerbation of systemic lupus erythematosus
- Exacerbation of Chorea
- Aggravation of varicose veins
- Pancreatitis
- Hepatocellular Carcinomas
- Changes in Serum Lipid levels, including hypertriglyceridemia
- Ischemic colitis
- Decrease in serum folate levels\*\*\*

\*\* Optic neuritis may lead to partial or complete loss of vision.

\*\*\*Serum folate levels may be depressed by COC therapy.

## **SYMPTOMS AND TREATMENT OF ACUTE OVERDOSAGE**

Symptoms of COC overdose in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; withdrawal bleeding may occur in females. There is no antidote and further treatment of overdose, if necessary, is directed to the symptoms.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

## **DOSAGE AND ADMINISTRATION**

### **OVRAL® 21 TABLETS REGIMEN**

Each cycle consists of 21 days on medication and a 7-day interval without medication (three weeks on, one week off).

The dosage of OVRAL tablets is one tablet daily for 21 consecutive days per menstrual cycle, according to prescribed schedule.

For the first cycle of medication, the patient is instructed to take one OVRAL tablets daily for 21 consecutive days beginning on Day 1 of her menstrual cycle, Day 5, or on the first Sunday after her period begins. (For the first cycle only, the first day of menstrual flow is considered Day 1.) The tablets are then discontinued for seven days (one week). Withdrawal bleeding should usually occur within three days following discontinuation of OVRAL.

The patient begins her next and all subsequent 21-day courses of OVRAL tablets (following the same 21 days on, 7 days off) on the same day of the week that she began her first course. She begins taking her tablets seven days after discontinuation, regardless of whether or not withdrawal bleeding is still in progress.

### **SPECIAL NOTES ON ADMINISTRATION**

It is recommended that OVRAL® tablets be taken at the same time each day, preferably after the evening meal or at bedtime.

OVRAL tablets are effective from the first day of therapy if the tablets are begun as described under "DOSAGE AND ADMINISTRATION".

If OVRAL tablets administration is initiated postpartum (no earlier than day 28 after delivery in the nonlactating mother) or after Day 1 of the first menstrual cycle, contraceptive reliance should not be placed on OVRAL until after the first seven consecutive days of administration. The possibility of ovulation and conception prior to initiation of medication should be considered. Therefore, nonhormonal methods of contraception (with the exception of the rhythm or temperature methods) should be used for the first 7 days of tablet taking. In the non-lactating mother, OVRAL may be prescribed in the postpartum period either immediately or at the first postpartum examination, whether or not menstruation has resumed.

If spotting or breakthrough bleeding occurs, the patient is instructed to continue on the same regimen. This type of bleeding usually is transient and without significance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her physician.

The patient should be instructed to use the following chart if she misses one or more of her birth control pills. She should be told to match the number of pills with the appropriate starting time for her type of pill.

<b>SUNDAY START</b>	<b>OTHER THAN SUNDAY START</b>
<p><b>Miss One Pill</b></p> <p>Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.</p>	<p><b>Miss One Pill</b></p> <p>Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.</p>
<p><b>Miss Two Pills in a Row</b></p> <p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Miss Two Pills in a Row</b></p> <p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>
<p><b>Miss Three or More Pills in a Row</b></p> <p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Miss Three or More Pills in a Row</b></p> <p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>

Contraceptive reliability may be reduced if active tablets are missed and particularly if the missed tablets extend the tablet-free interval. If active tablets were missed and intercourse took place in the week before the tablets were missed, the possibility of pregnancy should be considered.

**Advice in case of vomiting**

If vomiting occurs within 3 - 4 hours after tablet-taking, absorption may not be complete. In such event, advice concerning the Management of Missed Tablet is outlined in the above chart.

The woman must take the extra active tablet(s) needed from a backup pack.

**No hormonal contraceptive use (in the past month)**

Tablet-taking should start on day 1 of the woman's natural cycle (ie, the first day of her menstrual bleeding). Starting on days 2-7 is allowed, but for the first 7 days of tablet-taking during the first cycle, a nonhormonal back-up method of birth control (such as condoms and spermicide) is recommended.

**Changing from another oral contraceptive pill**

The woman should start OVRAL preferably on the day after the last active tablet of her previous oral contraceptive, but at the latest, on the day following the usual tablet-free or inactive tablet interval of her previous COC.

**Changing from a progestin only method (progestin-only pill, injection, implant)**

The woman may switch any day from the progestin-only pill and should begin OVRAL the next day. She should start OVRAL on the day of an implant removal or, if using an injection, the day the next injection would be due. In all of these situations, the woman should be advised to use a nonhormonal back-up method for the first 7 days of tablet-taking.

**Following first-trimester abortion**

The woman may start OVRAL immediately. Additional contraceptive measures are not needed.

**Following delivery or second-trimester abortion**

Since the immediate post-partum period is associated with an increased risk of thromboembolism, COC should be started no earlier than day 28 after delivery in the nonlactating mother or after second-trimester abortion. The woman should be advised to use a nonhormonal back-up method for the first 7 days of tablet-taking. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of COC use or the woman must wait for her first menstrual period.

## PHARMACEUTICAL INFORMATION

### DRUG SUBSTANCE


Proper Names: Norgestrel

Ethinyl Estradiol


Chemical Names: Norgestrel: 18,19-Dinorpregn-4-en-20-yn-3-one,13-ethyl-17-hydroxy-,(17a)-(±)-

Ethinyl Estradiol: 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol,(17a)-

Structural Formulae:



NORGESTREL



ETHINYL ESTRADIOL

Molecular Formulae: Norgestrel:  $C_{21}H_{28}O_2$

Ethinyl Estradiol:  $C_{20}H_{24}O_2$

Molecular Weights:	Norgestrel:	312.46
	Ethinyl Estradiol:	296.41
Solubility:	Norgestrel:	Sparingly soluble in alcohol, (USP Classification) insoluble in water.
	Ethinyl Estradiol:	Insoluble in water, soluble in alcohol, chloroform, ether, in vegetable oils and in solutions of fixed alkali hydroxides.
Melting Point:	Norgestrel:	205° - 212°C
	Ethinyl Estradiol:	180° - 186°C

#### Biological Properties:

Norgestrel: Unique, totally synthetic progestogen in which only the d-enantiomer is biologically active. The International Non-proprietary Name for this biologically active enantiomer, also referred to as d-norgestrel, is Levonorgestrel.

Ethinyl Estradiol: A semi-synthetic estrogen. The presence of the ethinyl group at C 17 on ring D of the steroid nucleus prevents enzymatic degradation of the estradiol molecule and results in an orally active compound.

## COMPOSITION

Non Medicinal Ingredients: Each OVRAL tablet contains Lactose, Magnesium Stearate, Microcrystalline Cellulose, Polacrillin Potassium.

## AVAILABILITY OF DOSAGE FORMS

<sup>Pr</sup>OVRAL® 21 tablets are available in 21-day regimen blister packages

Each package consists of 21 white OVRAL® tablets, each tablet containing 250 mcg of d-norgestrel (as 500 mcg of the dl-racemate) and 50 mcg ethinyl estradiol.

All tablets are engraved with  on one face and a "23" on the other face.

Store at 15° - 30° C.

OVRAL® should be protected from light once opened using the protective covering provided.

Keep out of reach of children.

---

**INFORMATION FOR THE CONSUMER**

---

**A. INFORMATION TO PATIENTS ON HOW TO TAKE THE BIRTH CONTROL  
PILL****1. READ THESE DIRECTIONS**

- before you start taking your pills, and
- any time you are not sure what to do.


**2. LOOK AT YOUR PILL PACK:**

- **21-PILL PACK:** 21 active pills (with hormones) taken daily for three weeks,  
and then take no pills for one week

**ALSO CHECK:****OVRAL® 21**

Take 1 tablet daily for 21 consecutive days, then discontinue tablets for seven days (one week).

Start by taking first tablet on appropriate day, as prescribed.



3. You may wish to use a second method of birth control (e.g. latex condoms and spermicidal foam or gel) for the first seven days of the first cycle of pill use. This will provide a back-up in case pills are forgotten while you are getting used to taking them.
4. When receiving any medical treatment, be sure to tell your doctor that you are using birth control pills.
5. **MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST THREE MONTHS ON THE PILL.** If you do feel sick, do not stop taking the pill. The problem will usually go away. If it does not go away, check with your doctor or clinic.

6. **MISSING PILLS ALSO CAN CAUSE SOME SPOTTING OR LIGHT BLEEDING,** even if you make up the missed pills. You also could feel a little sick to your stomach on the days you take two pills to make up for missed pills.
  
7. **IF YOU MISS PILLS AT ANY TIME, YOU COULD GET PREGNANT. THE GREATEST RISKS FOR PREGNANCY ARE:**
  - when you start a pack late
  - when you miss pills at the beginning or at the very end of the pack.
  
8. **ALWAYS BE SURE YOU HAVE READY:**
  - **ANOTHER KIND OF BIRTH CONTROL** (such as latex condoms and spermicidal foam or gel) to use as a back-up in case you miss pills, and
  
  - **AN EXTRA, FULL PACK OF PILLS.**
  
9. **IF YOU HAVE VOMITING OR DIARRHEA, OR IF YOU TAKE SOME MEDICINES,** such as antibiotics, your pills may not work as well. Use a back-up method, such as latex condoms and spermicidal foam or gel, until you can check with your doctor or clinic.
  
10. **IF YOU FORGET MORE THAN ONE PILL TWO MONTHS IN A ROW,** talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control.

**11. IF YOUR QUESTIONS ARE NOT ANSWERED HERE, CALL YOUR DOCTOR OR CLINIC.**

---

**WHEN TO START THE *FIRST* PACK OF PILLS**


---

**BE SURE TO READ THESE INSTRUCTIONS**

- before you start taking your pills, and
- any time you are not sure what to do.

Decide with your doctor or clinic what is the best day for you to start taking your first pack of pills.

Your pills are the 21-day type.



**OVRAL® 21**

**21-DAY COMBINATION**

With this type of birth control pill, you are 21 days on pills with seven days off pills. You must not be off the pills for more than seven days in a row.

- 1. THE FIRST DAY OF YOUR MENSTRUAL PERIOD (BLEEDING) IS DAY 1 OF YOUR CYCLE.** Your doctor may advise you to start taking the pills on Day 1, on Day 5, or on the first Sunday after your period begins. If your period starts on Sunday, start that same day. If OVRAL® tablets administration is initiated after Day 1 of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on OVRAL® until after the first seven active tablets have been taken for seven consecutive days. Nonhormonal methods of contraception (such as latex condoms and spermicidal foam or gel) should be used for the first 7 days of tablet taking.
- 2. Take one pill at approximately the same time every day for 21 days; THEN TAKE NO PILLS FOR SEVEN DAYS.** Start a new pack on the eighth day. You will probably have a period during the seven days off the pill. (This bleeding may be lighter and shorter than your usual period.)

---

### WHAT TO DO DURING THE MONTH

---

- 1. TAKE A PILL AT APPROXIMATELY THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.**
  - Try to associate taking your pill with some regular activity like eating a meal or going to bed.

- Do not skip pills even if you have bleeding between monthly periods or feel sick to your stomach (nausea).
- Do not skip pills even if you do not have sex very often.

**2. WHEN YOU FINISH A PACK:**

**WAIT SEVEN DAYS** to start the next pack. You will have your period during that week.

---

**WHAT TO DO IF YOU MISS PILLS**

---

The following chart outlines the actions you should take if you miss one or more of your birth control pills. Match the number of pills missed with the appropriate starting time for your type of pill pack.

SUNDAY START	OTHER THAN SUNDAY START
<p><b>Miss One Pill</b></p> <p>Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.</p>	<p><b>Miss One Pill</b></p> <p>Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.</p>
<p><b>Miss Two Pills in a Row</b></p> <p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Miss Two Pills in a Row</b></p> <p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>
<p><b>Miss Three or More Pills in a Row</b></p> <p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Miss Three or More Pills in a Row</b></p> <p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>

Always be sure you have on hand:

- a nonhormonal back-up method of birth control (such as latex condoms and spermicidal foam or gel) in case you miss pills, and
- an extra, full pack of pills.

**IF YOU FORGET MORE THAN ONE PILL TWO MONTHS IN A ROW, TALK TO YOUR DOCTOR OR CLINIC** about ways to make pill-taking easier or about using another method of birth control.

### **OVERDOSAGE**

Symptoms of overdose of birth control pills in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; vaginal bleeding may occur in females. Contact your doctor, your hospital or your local Poison Control Centre in case of accidental overdose.

\*\*\*\*\*

**B. PACKAGE INSERT FOR PATIENTS****USING ORAL CONTRACEPTIVES****(BIRTH CONTROL PILLS)**

You should know that a supplementary information booklet which describes the benefits and risks of taking birth control pills (oral contraceptives) is available from your doctor or pharmacist. Be sure to obtain a copy and read it carefully before you start taking these pills.

OVRAL® is a birth control pill (oral contraceptive) which contains 2 female sex hormones, in a specific ratio. Each white tablet contains 250 mcg d-norgestrel (as 500 mcg of dl-racemate) and 50 mcg ethinyl estradiol. It has been shown to be highly effective in preventing pregnancy when taken as prescribed by your doctor. Pregnancy is always more risky than taking birth control pills, except in smokers older than age 35.

The birth control pill is not suitable for every woman. In a small number of women, serious side effects may occur. Your doctor can advise you if you have any conditions that would pose a risk to you. The use of the birth control pill always should be supervised by your doctor.

You should not use birth control pills if you have or have had any of the following conditions:

- unusual vaginal bleeding that has not yet been diagnosed;
- blood clots in the legs, lungs, eyes, or elsewhere;
- a stroke, heart attack, or chest pain (angina pectoris);
- hereditary or acquired blood clotting disorders;
- heart valve or heart rhythm disorders that may be associated with formation of blood clots;
- migraines with neurological symptoms, such as aura;
- partial or complete loss of vision or other vision problems caused by a vascular disease;
- known or suspected cancer of the breast or sex organs;
- a liver tumour associated with the use of the pill or other estrogen-containing products; and/or
- jaundice or liver disease if still present;
- diabetes affecting your circulation;
- uncontrolled high blood pressure;
- allergy or hypersensitivity to any of the components of OVRAL® (including norgestrel and ethinyl estradiol).

The pill should not be taken if you are pregnant or if pregnancy is suspected.

**If you decide to take birth control pills**

If you and your doctor decide that, for you, the benefits of birth control pills outweigh the risks, you should be aware of the following:

<p>1. Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels. This risk increases with age and becomes significant in birth control pill users over 35 years of age. Women should not smoke.</p>
--

2. Take the pills only on the advice of your doctor and carefully follow all directions given to you.

You must take the pills exactly as prescribed. Otherwise, you may become pregnant.

3. Visit your doctor three months or sooner after the initial examination. Afterward, visit your doctor at least once a year.

4. Be alert for the following symptoms and signs of serious adverse effects. Call your doctor immediately if they occur:

- sharp pain in the chest, coughing blood, or sudden shortness of breath. These symptoms could indicate a possible blood clot in the lung;
- pain in the calf. This symptom could indicate a possible blood clot in the leg;
- crushing chest pain or heaviness. This symptom could indicate a possible heart attack;

- sudden severe or worsening headache or vomiting, dizziness or fainting, disturbance of vision or speech, or weakness or numbness in an arm or leg. These symptoms could indicate a possible stroke;
- sudden partial or complete loss of vision. This symptom could indicate a possible blood clot in the eye;
- severe pain or lump in the abdomen. These symptoms could indicate a possible tumour of the liver;
- severe depression;
- yellowing of the skin (jaundice);
- nausea, vomiting, and abdominal pain. These symptoms could indicate liver injury (e.g., hepatitis, hepatic function abnormal);
- unusual swelling of the extremities; and/or
- breast lumps. **ASK YOUR DOCTOR FOR ADVICE AND INSTRUCTION ON**

**REGULAR SELF-EXAMINATION OF YOUR BREASTS.**

5. Birth control pills should never be taken if you think you are pregnant. They will not prevent the pregnancy from continuing.
6. You will have a menstrual period when you stop taking birth control pills. You should delay pregnancy until another menstrual period occurs within four to six weeks. Contact your doctor for recommendations on alternate methods of contraception during this time.

7. Your doctor will advise you of the appropriate time to start the use of birth control pills after childbirth, miscarriage, or therapeutic abortion.
  
8. The hormones in birth control pills are known to appear in breast milk. These hormones may decrease the flow of breast milk.. The use of oral contraceptives is generally not recommended until the nursing mother has completely weaned her child.
  
9. Should you require **MAJOR** surgery, inform your surgeon that you are using birth control pills.
  
10. **If you see a different doctor, inform him or her that you are taking birth control pills.**  
  
Tell the doctor that your birth control pills are OVRAL.

**11. Inform your doctor if you are taking or if you start to take other medications.**

**This applies to both prescription and non-prescription drugs.** These medications may change the effectiveness and/or cycle control of your birth control pills. **You may need to use a back-up method of birth control.**

12. **THERE IS NO NEED TO STOP TAKING BIRTH CONTROL PILLS FOR A REST PERIOD.**

13. Birth control pills **DO NOT PROTECT** against sexually transmitted diseases (STDs), including HIV/AIDS. For protection against STDs, it is advisable to use latex condoms **IN COMBINATION WITH** birth control pills.

---

### HOW TO TAKE BIRTH CONTROL PILLS

---

1. **READ THESE DIRECTIONS**

- before you start taking your pills, and
- any time you are not sure what to do.


2. **LOOK AT YOUR PILL PACK:**

- **21-PILL PACK:** 21 active pills (with hormones) taken daily for three weeks, and then take no pills for one week.

**ALSO CHECK:****OVRAL® 21**

Take 1 tablet daily for 21 consecutive days, then discontinue tablets for seven days (one week).

Start by taking first tablet on appropriate day, as prescribed.



3. You may wish to use a second method of birth control (e.g. latex condoms and spermicidal foam or gel) for the first seven days of the first cycle of pill use. This will provide a back-up in case pills are forgotten while you are getting used to taking them.
4. **When receiving any medical treatment, be sure to tell your doctor that you are using birth control pills.**
5. **MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST THREE MONTHS ON THE PILL.** If you do feel sick, do not stop taking the pill. The problem will usually go away. If it does not go away, check with your doctor or clinic.

6. **MISSING PILLS ALSO CAN CAUSE SOME SPOTTING OR LIGHT BLEEDING,** even if you make up the missed pills. You also could feel a little sick to your stomach on the days you take two pills to make up for missed pills.
  
7. **IF YOU MISS PILLS AT ANY TIME, YOU COULD GET PREGNANT. THE GREATEST RISKS FOR PREGNANCY ARE:**
  - when you start a pack late, or
  - when you miss pills at the beginning or at the very end of the pack.
  
8. **ALWAYS BE SURE YOU HAVE READY:**
  - **ANOTHER KIND OF BIRTH CONTROL** (such as latex condoms and spermicidal foam or gel) to use as a back-up in case you miss pills, and
  - **AN EXTRA, FULL PACK OF PILLS.**
  
9. **IF YOU EXPERIENCE VOMITING OR DIARRHEA, OR IF YOU TAKE CERTAIN MEDICINES,** such as antibiotics, your pills may not work as well. Use a back-up method, such as latex condoms and spermicidal foam or gel, until you can check with your doctor or clinic.

10. **IF YOU FORGET MORE THAN ONE PILL TWO MONTHS IN A ROW**, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control.
11. **IF YOUR QUESTIONS ARE NOT ANSWERED HERE, CALL YOUR DOCTOR OR CLINIC.**

---


**WHEN TO START THE *FIRST* PACK OF PILLS**

---

BE SURE TO READ THESE INSTRUCTIONS:

- before you start taking your pills, and
- any time you are not sure what to do.

Decide with your doctor or clinic what is the best day for you to start taking your first pack of pills. Your pills are the 21-day type.



## OVRAL® 21

### 21-DAY COMBINATION

With this type of birth control pill, you are on pills for 21 days and off pills for seven days.

You must not be off the pills for more than seven days in a row.

1. **THE FIRST DAY OF YOUR MENSTRUAL PERIOD (BLEEDING) IS DAY 1 OF YOUR CYCLE.** Your doctor may advise you to start taking the pills on Day 1, on Day 5, or on the first Sunday after your period begins. If your period starts on Sunday, start that same day. If OVRAL® tablets administration is initiated after Day 1 of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on OVRAL® until after the first seven active tablets have been taken for seven consecutive days. Nonhormonal methods of contraception (such as latex condoms and spermicidal foam or gel) should be used for the first 7 days of tablet taking.
2. Take one pill at approximately the same time every day for 21 days, **THEN TAKE NO PILLS FOR SEVEN DAYS.** Start a new pack on the eighth day. You will probably have

a period during the seven days off the pill. (This bleeding may be lighter and shorter than your usual period.)

---

### WHAT TO DO DURING THE MONTH

---

1. **TAKE A PILL AT APPROXIMATELY THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.**

- Try to associate taking your pill with some regular activity like eating a meal or going to bed.
- Do not skip pills even if you have bleeding between monthly periods or feel sick to your stomach (nausea).
- Do not skip pills even if you do not have sex very often.

2. **WHEN YOU FINISH A PACK:**

**WAIT SEVEN DAYS** to start the next pack. You will have your period during that week.

---

## WHAT TO DO IF YOU MISS PILLS

The following outlines the actions you should take if you miss one or more of your birth control pills. Match the number of pills missed with the appropriate starting time for your type of pill pack.

SUNDAY START	OTHER THAN SUNDAY START
<b>Miss One Pill</b>	<b>Miss One Pill</b>
Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.	Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.
<b>Miss Two Pills in a Row</b>	<b>Miss Two Pills in a Row</b>
<p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>
<b>Miss Three or More Pills in a Row</b>	<b>Miss Three or More Pills in a Row</b>
<p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>

Always be sure you have on hand:

- a nonhormonal back-up method of birth control (such as latex condoms and spermicidal foam or gel) in case you miss pills, and
- an extra, full pack of pills.

**IF YOU FORGET MORE THAN ONE PILL TWO MONTHS IN A ROW, TALK TO YOUR DOCTOR OR CLINIC** about ways to make pill-taking easier or about using another method of birth control.

### **OVERDOSAGE**

Symptoms of overdose of birth control pills in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; vaginal bleeding may occur in females. Contact your doctor, your hospital or your local Poison Control Centre in case of accidental overdose.

\*\*\*\*\*

**C. SUPPLEMENTARY INFORMATION BOOKLET**  
**FOR PATIENTS CONSIDERING THE USE OF ORAL CONTRACEPTIVES**  
**(BIRTH CONTROL PILLS)**

**Introduction**

This booklet will give you information to make an informed choice on the use of oral contraceptives.

Oral contraceptives are also known as birth control pills or "the pill."

You should read this booklet if you are thinking about any method of birth control. If you have decided to take birth control pills, this booklet will help you understand both the risks and the benefits. It also will give you information on how to use birth control pills.

When taken as directed, birth control pills are a very effective way to prevent pregnancy. Only sterilization is more effective. The pill is convenient and has many benefits other than birth control. Most women do not develop serious and unpleasant side effects from using birth control pills.

The pill has important advantages over other methods of birth control. It also has certain risks that no other method has. Your doctor is the best person to explain the consequences of any possible risks. You can help your doctor prescribe birth control pills as safely as possible. Tell your doctor about yourself, and be alert for the earliest signs of possible trouble.

Read this booklet carefully and discuss its contents with your doctor.
--

## **Types of birth control pills**

There are two types of birth control pills:

1. The "combination pill" is the most common type. It contains two female sex hormones - an estrogen and a progestin. The amounts and types of estrogen and progestin differ from one preparation to another. The amount of estrogen is more important. The effectiveness and some dangers of birth control pills are related mainly to the amount of estrogen.
2. The "mini-pill" is the second type. It contains only one female sex hormone - a progestin.

## **How birth control pills work**

Birth control pills work in two ways:

1. They inhibit the monthly release of an egg by the ovaries.
2. They change the mucus produced by the cervix. This slows the movement of the sperm through the mucus and through the uterus (womb).

## **Effectiveness of birth control pills**

Combination birth control pills are more than 99 percent effective in preventing pregnancy when

- the pill is **TAKEN AS DIRECTED**, and
- the amount of estrogen is 20 micrograms or more.

A 99 percent effectiveness rate means that if 100 women used birth control pills for one year, one woman in the group would get pregnant.

The mini-pill (progestin only) is slightly less effective than combination birth control pills.

### **Other ways to prevent pregnancy**

Other methods of birth control are available to you. They are usually less effective than birth control pills. Used properly, however, other methods of birth control are effective enough for many women.

The following table gives reported pregnancy rates for various forms of birth control, including no birth control. The reported rates represent the number of women out of 100 who would become pregnant in one year.

#### **Reported Pregnancies per 100 Women per Year**

Combination pill	less than 1 to 2
Intrauterine device (IUD)	less than 1 to 6
Condom with spermicidal foam or gel	1 to 6
Mini-pill	3 to 6
Condom	2 to 12
Diaphragm with spermicidal foam or gel	3 to 18
Spermicide	3 to 21
Sponge with spermicide	3 to 28
Cervical cap with spermicide	5 to 18
Periodic abstinence (rhythm), all types	2 to 20
No birth control	60 to 85

Pregnancy rates vary widely because people differ in how carefully and regularly they use each method. (This does not apply to IUDs since they are implanted in the uterus.) Regular users may achieve pregnancy rates in the lower ranges. Others may expect pregnancy rates more in the middle ranges.

The effective use of birth control methods other than birth control pills and IUDs requires more effort than taking a single pill every day. It is an effort that many couples undertake successfully.

### **Who should not use birth control pills**

You should not use birth control pills if you have or have had any of the following conditions:

- unusual vaginal bleeding that has not yet been diagnosed;
- blood clots in the legs, lungs, eyes, or elsewhere;
- a stroke, heart attack or chest pain (angina pectoris);
- hereditary or acquired blood clotting disorders;
- heart valve or heart rhythm disorders that may be associated with formation of blood clots;
- migraines with neurological symptoms, such as aura;
- partial or complete loss of vision or other vision problems caused by a vascular disease;
- known or suspected cancer of the breast or sex organs;
- liver tumour associated with the use of birth control pills or other estrogen-containing products; and/or
- jaundice or liver disease if still present;

- diabetes affecting your circulation;
- uncontrolled high blood pressure;
- allergy or hypersensitivity to any of the components of OVRAL® (including norgestrel and ethinyl estradiol).

The pill should not be taken if you are pregnant or if pregnancy is suspected.

There are also conditions that your doctor will want to watch closely or that might cause your doctor to recommend a method of contraception other than birth control pills:

- breast conditions:
  - a strong family history of breast cancer
  - breast disorders including pain, discharge from the nipples, thickenings, or

lumps. In some circumstances, benefit may be derived from taking the pill; in other cases, adverse effects may follow.

- diabetes
- high blood pressure
- abnormal levels of fats in the bloodstream (high cholesterol or triglycerides)
- cigarette smoking
- migraines with neurological symptoms, such as aura (current or history);
- heart or kidney disease
- epilepsy
- depression
- fibroid tumours of the uterus
- gallbladder or pancreatic disease

- plans for forthcoming surgery
- history of jaundice or other liver disease
- obesity

You also should inform your doctor about a family history of blood clots, heart attacks or strokes.

### **The risks of birth control pills**

#### 1. *Circulatory disorders (including blood clots in legs, lungs, heart, eyes or brain)*

Blood clots are the most common serious side effect of birth control pills. Clots can occur in many areas of the body.

- In the brain, a clot can result in a stroke.
- In a blood vessel of the heart, a clot can result in a heart attack.
- In the legs and pelvis, a clot can break off and travel to the lung resulting in a pulmonary embolus.
- In a blood vessel leading to an arm or leg, a clot can result in damage to or loss of a limb.

Any of these conditions can cause death or disability. Clots also occur rarely in the blood vessels of the eye, resulting in blindness or impaired vision.

Women who use birth control pills have a higher incidence of blood clots. The risk of clotting seems to increase with higher estrogen doses. **It is important, therefore, to use as low a dosage of estrogen as possible.**

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels. This risk increases with age and becomes significant in birth control pill users over 35 years of age. Women should not smoke.

## 2. *Breast cancer*

The most significant risk factors for breast cancer are increasing age and a strong history of breast cancer in the family (mother or sister). Other established risk factors include obesity, never having children, and having your first full-term pregnancy at a late age.

Some women who use birth control pills may be at increased risk of developing breast cancer before menopause, which occurs around age 50. These women may be long-term users of birth control pills (more than eight years) or women who start using birth control pills at an early age. In a few women, the use of birth control pills may accelerate the growth of an existing but undiagnosed breast cancer. Breast cancer has been diagnosed slightly more often in women who use the Pill than in women of the same age who do not use the Pill. This slight increase in the numbers of breast cancer diagnoses gradually disappears during the course of the 10 years after stopping use of the Pill. It is not known whether the difference is caused by the Pill. It may be that the women were examined more often, so that the breast cancer was noticed earlier. Early diagnosis, however, can reduce the effect of

breast cancer on a woman's life expectancy. The potential risks related to birth control pills seem to be small, however.

Women with the following conditions should be examined yearly by their doctors no matter what method of contraception they use:

- a strong history of breast cancer in the family;
- breast nodules or thickenings; and/or
- discharge from the nipple.

3. ***Dangers to developing child if birth control pills are used during pregnancy***

Birth control pills should not be taken by pregnant women. There is no evidence, however, that the pill can damage a developing child.

There is also no evidence that the use of birth control pills immediately before a pregnancy will adversely affect a baby's development. When a woman stops taking birth control pills to become pregnant, however, her doctor may recommend a different method of contraception until she has a period on her own. In this way, the pregnancy can be more accurately dated.

4. ***Gallbladder disease and liver tumours***

Users of birth control pills have a greater risk of developing gallbladder disease requiring surgery within the first year of use. The risk may double after four or five years of use.

The short and long-term use of birth control pills also has been linked with the growth of liver tumours. Such tumours are **EXTREMELY** rare.

5. *Other side effects of birth control pills*

Some users of birth control pills have unpleasant side effects. These side effects are temporary and are not hazardous to health.

There may be tenderness of the breasts, nausea, and vomiting. Some users will experience weight gain or loss. Many of these side effects occurred with high dose combination birth control pills. These side effects are less common with the low-dose pills prescribed today. Unexpected vaginal bleeding or spotting and changes in the usual menstrual period also may occur. These side effects usually disappear after the first few cycles. They are **not** an indication to stop taking birth control pills. Unless more significant complications occur, a decision to stop using the pill or to change the brand of pill should be made only after three consecutive months of use. Occasionally, users develop high blood pressure that may require stopping the use of birth control pills.

Other side effects may include

- growth of pre-existing fibroid tumours of the uterus;
- depression;
- liver problems with jaundice (yellowing of the skin);
- an increase or decrease in hair growth, sex drive and appetite;
- skin pigmentation;

- headaches;
- rash; and/or
- vaginal infections.

Infrequently, there is a need to change contact lens prescription or an inability to use contact lenses.

A woman's menstrual period may be delayed after stopping birth control pills. There is no evidence that the use of the pill leads to a decrease in fertility. As mentioned, it is wise to delay starting a pregnancy for one menstrual period after stopping birth control pills.

### **Non-contraceptive benefits of birth control pills**

Several health advantages have been linked to the use of birth control pills.

- Combination estrogen and progestin birth control pills reduce the incidence of cancer of the uterus and ovaries.
- Birth control pills reduce the likelihood of developing benign (non-cancerous) breast disease and ovarian cysts.
- Users of birth control pills lose less menstrual blood and have more regular cycles. The risk of developing iron-deficiency anemia is thus reduced.
- There may be a decrease in painful menstruation and premenstrual syndrome (PMS).

- Acne, excessive hair growth and male-hormone-related disorders also may be improved.

Birth control pills **DO NOT PROTECT** against sexually transmitted diseases (STDs), including HIV/AIDS. For protection against STDs, it is advisable to use latex condoms **IN COMBINATION WITH** birth control pills.

### **Periodic examination**

A complete medical and family history is necessary before birth control pills are prescribed. A physical examination should include measuring blood pressure and examining the breasts, abdomen, pelvic organs, and limbs.

A second visit to your doctor should take place three months or sooner after starting birth control pills. During this visit, any side effects should be evaluated and your blood pressure checked again. Afterward, an annual examination similar to the first visit is recommended. A Pap smear is usually taken before starting birth control pills and then at intervals recommended by your doctor.

### **If you decide to take birth control pills**

If you and your doctor decide that, for you, the benefits of birth control pills outweigh the risks, you should be aware of the following:

1. Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels. This risk increases with age and becomes significant in birth control pill users older than 35 years of age. Women should not smoke.

2. Take the pills only on the advice of your doctor and carefully follow all directions given to you. You must take the pills exactly as prescribed. Otherwise, you may become pregnant.
3. Visit your doctor three months or sooner after the initial examination. Afterward, visit your doctor at least once a year.
4. Be alert for the following symptoms and signs of serious adverse effects. Call your doctor immediately if they occur:
  - sharp pain in the chest, coughing blood, or sudden shortness of breath. These symptoms could indicate a possible blood clot in the lung;
  - pain in the calf. This symptom could indicate a possible blood clot in the leg;
  - crushing chest pain or heaviness. This symptom could indicate a possible heart attack;
  - sudden severe or worsening headache or vomiting, dizziness or fainting, disturbance of vision or speech, or weakness or numbness in an arm or leg. These symptoms could indicate a possible stroke;

- sudden partial or complete loss of vision. This symptom could indicate a possible blood clot in the eye;
  - severe pain or lump in the abdomen. These symptoms could indicate a possible tumour of the liver;
  - severe depression;
  - yellowing of the skin (jaundice);
  - nausea, vomiting, and abdominal pain. These symptoms could indicate liver injury (e.g., hepatitis, hepatic function abnormal);
  - unusual swelling of the extremities; and/or
  - breast lumps. **ASK YOUR DOCTOR FOR ADVICE AND INSTRUCTION ON REGULAR SELF-EXAMINATION OF YOUR BREASTS.**
5. Birth control pills should never be taken if you think you are pregnant. They will not prevent the pregnancy from continuing.

6. You will have a menstrual period when you stop taking birth control pills. You should delay pregnancy until another menstrual period occurs within four to six weeks. Contact your doctor for recommendations on alternate methods of contraception during this time.
7. Your doctor will advise you of the appropriate time to start the use of birth control pills after childbirth, miscarriage, or therapeutic abortion.
8. The hormones in birth control pills are known to appear in breast milk. These hormones may decrease the flow of breast milk. The use of OCs is generally not recommended until the nursing mother has completely weaned her child .
9. Should you require **MAJOR** surgery, inform your surgeon that you are using birth control pills.
10. **If you see a different doctor, inform him or her that you are taking birth control pills.**  
Tell the doctor that your birth control pills are **OVRAL®**.

**11. Inform your doctor if you are taking or if you start to take other medications. This applies to both prescription and non-prescription drugs.** These medications may change the effectiveness and/or cycle control of your birth control pills. **You may need to use a back-up method of birth control.**

12. **THERE IS NO NEED TO STOP TAKING BIRTH CONTROL PILLS FOR A REST PERIOD.**

13. Birth control pills **DO NOT PROTECT** against sexually transmitted diseases (STDs), including HIV/AIDS. For protection against STDs, it is advisable to use latex condoms **IN COMBINATION WITH** birth control pills.

---

### HOW TO TAKE BIRTH CONTROL PILLS

---

1. **READ THESE DIRECTIONS**

- before you start taking your pills, and
- any time you are not sure what to do.

2. **LOOK AT YOUR PILL PACK:**


- **21-PILL PACK:** 21 active pills (with hormones) taken daily for three weeks, and then take no pills for one week.

**ALSO CHECK:**

**OVRAL® 21**

Take 1 tablet daily for 21 consecutive days, then discontinue tablets for seven days (one week).

Start by taking first tablet on appropriate day, as prescribed.



3. You may wish to use a second method of birth control (e.g. latex condoms and spermicidal foam or gel) for the first seven days of the first cycle of pill use. This will provide a back-up in case pills are forgotten while you are getting used to taking them.
4. **When receiving any medical treatment, be sure to tell your doctor that you are using birth control pills.**
5. **MANY WOMEN HAVE SPOTTING OR LIGHT BLEEDING, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST THREE MONTHS ON THE PILL.** If you do feel sick, do not stop taking the pill. The problem will usually go away. If it does not go away, check with your doctor or clinic.
6. **MISSING PILLS ALSO CAN CAUSE SOME SPOTTING OR LIGHT BLEEDING,** even if you make up the missed pills. You also could feel a little sick to your stomach on the days you take two pills to make up for missed pills.
7. **IF YOU MISS PILLS AT ANY TIME, YOU COULD GET PREGNANT. THE GREATEST RISKS FOR PREGNANCY ARE:**

- when you start a pack late; or
  - when you miss pills at the beginning or at the very end of the pack.
8. **ALWAYS BE SURE YOU HAVE READY:**
- **ANOTHER KIND OF BIRTH CONTROL** (such as latex condoms and spermicidal foam or gel) to use as a back-up in case you miss pills, and
  - **AN EXTRA, FULL PACK OF PILLS.**
9. **IF YOU EXPERIENCE VOMITING OR DIARRHEA, OR IF YOU TAKE SOME MEDICINES**, such as antibiotics, your pills may not work as well. Use a back-up method, such as latex condoms and spermicidal foam or gel, until you can check with your doctor or clinic.
10. **IF YOU FORGET MORE THAN ONE PILL TWO MONTHS IN A ROW**, talk to your doctor or clinic about how to make pill-taking easier or about using another method of birth control.
11. **IF YOUR QUESTIONS ARE NOT ANSWERED HERE, CALL YOUR DOCTOR OR CLINIC.**

---

**WHEN TO START THE *FIRST* PACK OF PILLS**


---

**BE SURE TO READ THESE INSTRUCTIONS:**

- before you start taking your pills, and
- any time you are not sure what to do.

Decide with your doctor or clinic what is the best day for you to start taking your first pack of pills.

Your pills are the 21-day type.

**OVRAL® 21 tablets****21-DAY COMBINATION**

With this type of birth control pill, you are on pills for 21 days and off pills for seven days. You must not be off the pills for more than seven days in a row.

1. **THE FIRST DAY OF YOUR MENSTRUAL PERIOD (BLEEDING) IS DAY 1 OF YOUR CYCLE.** Your doctor may advise you to start taking the pills on Day 1, on Day 5, or on the first Sunday after your period begins. If your period starts on Sunday, start that same day. If OVRAL® tablets administration is initiated after Day 1 of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on OVRAL® until after the first seven active tablets have been taken for seven consecutive days. Nonhormonal methods of

contraception (such as latex condoms and spermicidal foam or gel) should be used for the first 7 days of tablet taking.

2. Take one pill at approximately the same time every day for 21 days; **THEN TAKE NO PILLS FOR SEVEN DAYS.** Start a new pack on the eighth day. You will probably have a period during the seven days off the pill. (This bleeding may be lighter and shorter than your usual period.)

---

### WHAT TO DO DURING THE MONTH

---

1. **TAKE A PILL AT APPROXIMATELY THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.**

- Try to associate taking your pill with some regular activity like eating a meal or going to bed.
- Do not skip pills even if you have bleeding between monthly periods or feel sick to your stomach (nausea).
- Do not skip pills even if you do not have sex very often.

2. **WHEN YOU FINISH A PACK:**

WAIT SEVEN DAYS to start the next pack. You will have your period during that week.

---

---

## WHAT TO DO IF YOU MISS PILLS

The following outlines the actions you should take if you miss one or more of your birth control pills.

Match the number of pills missed with the appropriate starting time for your type of pill pack.

SUNDAY START	OTHER THAN SUNDAY START
<p><b>Miss One Pill</b></p> <p>Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.</p>	<p><b>Miss One Pill</b></p> <p>Take it as soon as you remember, and take the next pill at the usual time. This means that you might take two pills in one day.</p>
<p><b>Miss Two Pills in a Row</b></p> <p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Miss Two Pills in a Row</b></p> <p><b>First two weeks</b></p> <ol style="list-style-type: none"> <li>1. Take two pills the day you remember and two pills the next day.</li> <li>2. Then take one pill a day until you finish the pack.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> </ol> <p><b>Third week</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>

Miss Three or More Pills in a Row	Miss Three or More Pills in a Row
<p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Keep taking one pill a day until Sunday.</li> <li>2. On Sunday, safely discard the rest of the pack and start a new pack that day.</li> <li>3. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>4. You may not have a period this month.</li> </ol> <p><b>If You Miss Two periods in a Row, Call Your Doctor or Clinic.</b></p>	<p><b>Anytime in the cycle</b></p> <ol style="list-style-type: none"> <li>1. Safely dispose of the rest of the pill pack and start a new pack that same day.</li> <li>2. Use a nonhormonal back-up method of birth control if you have sex in the seven days after you miss the pills.</li> <li>3. You may not have a period this month.</li> </ol> <p><b>If You Miss Two Periods in a Row, Call Your Doctor or Clinic.</b></p>

Always be sure you have on hand:

- a nonhormonal back-up method of birth control (such as latex condoms and spermicidal foam or gel) in case you miss pills, and
- an extra, full pack of pills.

**IF YOU FORGET MORE THAN ONE PILL TWO MONTHS IN A ROW, TALK TO YOUR DOCTOR OR CLINIC.** Talk about ways to make pill-taking easier or about using another method of birth control.

Store at 15° - 30° C.

OVRAL® should be protected from light once opened using the protective covering provided.

Keep out of reach of children.

\*\*\*\*\*

## CLINICAL TRIALS

The contraceptive efficacy and safety of OVRAL® has been evaluated in multicentre clinical trials.

A total of 6,806 patients completed 127,872 cycles with OVRAL®: 4,961 completed 6 cycles, 3,754 completed 12 cycles, 2,642 completed 18 cycles, 1,876 completed 24 cycles and 118 completed 90 cycles. (See Table 1).

No pregnancies were reported that could be attributed to medication failure. The 19 pregnancies that were reported in treatment cycles were all associated with omission of tablets. The overall pregnancy rate calculated by the Life Table Method is 0.7 and the Pearl Index is 0.16 per 100 woman-years. The corrected pregnancy rate (excluding the 19 pregnancies all classified as patient failures) is 0 as calculated by the Life Table Method and the corrected Pearl Index is 0 per 100 woman-years.

The withdrawal bleeding pattern was maintained in a regular manner. The mean length of the "menstrual cycle" was 28 days, the mean duration of the "menstrual period" 4 to 5 days, with an average amount of "menstrual flow" in 82.9% of the cycles, light flow in 11.3% and heavy flow in 5.8%. The latent period between the taking of the last pill in a cycle and the onset of the period averaged 3.4 days.

Commonly associated side effects that occur during the use of oral contraceptives and with OVRAL® are listed by percentage of their occurrence in each cycle in Tables 2 and 3.

Spotting or breakthrough bleeding was infrequent and usually mild and self-limited. The medication should not be halted during such occurrences. If the bleeding persists, the usual diagnostic procedures should be undertaken to determine the cause of the vaginal bleeding.

The incidence of amenorrhea was very low with the use of OVRAL®. It can occur following an episode of breakthrough bleeding in the preceding cycle or may be unrelated to a previous bleeding episode. If one period is missed, appropriate diagnostic procedures should be undertaken to rule out pregnancy and medication should be discontinued during this time and an alternate method of contraception employed. Prompt return to fertility has been demonstrated following discontinuation of therapy with OVRAL®.

TABLE 1: HISTOGRAM OF NUMBER OF WOMEN  
BY NUMBER OF CYCLES COMPLETED




TABLE 2: SIDE EFFECTS COMMONLY REPORTED DURING USE OF  
ORAL CONTRACEPTIVES

AS REPORTED WITH OVRAL®

SYMPTOM	CYCLE I (%)	TOTAL CYCLES (%)	NO. DROPOUTS
Weight gain (5 lb)	7.2	3.9	18
Dysmenorrhea	9.8	3.8	4
Headache	7.6	3.4	40
Weight Loss (5 lb)	2.4	2.5	3
Nausea/Vomiting	9.9	1.5	39
Dizziness	4.7	1.2	11
Libido, Increase	1.2	0.1	0
Libido, Decrease	0.6	0.1	10
Depression	0.5	0.1	2
Nervousness	0.3	0.1	16
Gastrointestinal discomfort	0.2	0.1	11
Vaginal Discharge/Pruritus	0.2	0.1	6
Muscle/Joint aches	0.1	0.1	0

NOTE: Other side effects were reported, but in an incidence less than 0.1 percent of total cycles.

TABLE 3: INCIDENCE OF MENSTRUAL IRREGULARITIES

SYMPTOM	PERCENT OF SUBJECTS									% OF TOTAL CYCLES
	C Y C L E									
	1	12	24	36	48	60	72	84	96	
Spotting	5.0	1.3	0.7	1.4	0.8	1.1	1.9	1.9	1.7	1.5
Breakthrough Bleeding	2.7	1.1	0.6	0.7	0.2	1.1	0.4	0.6	0.0	1.0
Amenorrhea	0.9	0.5	0.6	0.6	1.1	1.3	0.0	0.6	0.0	0.7

## **CLINICAL LABORATORY RESULTS**

### **Liver Function Tests**

The results of hepatic function tests indicate that increased BSP retention and elevations of aspartate serum transaminase (AST) and alkaline phosphatase and gamma glutamine transaminase (GGT) can be expected to occur in some patients taking OVRAL® as with other oral contraceptives. BSP tests were performed in 160 patients; AST in 3,113; GGT in 3,158. These tests cannot be considered reliable when used to evaluate liver function in patients taking oral contraceptives. No patient developed symptoms or evidence, on physical examination, of liver disease while taking OVRAL®. The results of serum bilirubin, serum alkaline phosphatase, cephalin flocculation and thymol turbidity determinations in patients taking OVRAL® reveal no significant variations from pretreatment values. Serum bilirubin tests were performed in 6,401 patients; serum alkaline phosphatase in 6,265; cephalin flocculation in 97; and thymol turbidity in 57. Total serum protein and A/G ratio were normal in more than 2,000 patients during treatment.

### **Thyroid**

As with other oral contraceptives, slight increases in protein-bound iodine determinations were reported in patients taking OVRAL®. PBI tests were performed in 306 patients. In the series of clinical investigations 6.9% of control determinations were elevated beyond normal limits (4-8 mg%) while on treatment 10.9% of the determinations were reported to be elevated. No clinical symptom complex of hyperthyroidism (nervousness, weakness, sensitivity to heat, sweating, restless activity, weight loss, increased appetite, headache, palpitations, tremor, nausea, abdominal pain, polyuria, prominence of the eyes) developed in any patient with an elevated determination

during treatment. It is thought that the increases in protein-bound iodine are due to an increased thyroxin-binding globulin activity induced by the addition of exogenous estrogen.

### **Renal Function**

No findings of significance were observed in the results of the urinalyses and blood urea nitrogen determinations made during the course of OVRAL® administration. Urinalyses were performed in 5,776 patients and BUN in 6,249.

### **Calcium and Phosphorus Serum Levels**

Serum calcium and phosphorus were determined in 98 patients while taking OVRAL®. There were no significant changes from pretreatment levels.

### **Coagulation Tests**

The results of a panel of nine coagulation tests performed on blood samples from 68 patients taking OVRAL® at three-month intervals for as long as eighteen months suggest a trend toward lower average clotting times in plastic tubes and average partial thromboplastin times. The means for these tests, however, remained within the normal range of values and the above findings were not found to be clinically significant except in two individuals with co-existent thrombophlebitis, a contraindication to the use of oral contraceptives (See CONTRAINDICATIONS No. 1). There were no significant changes in the remainder of the panel of coagulation tests.

**Adrenal Function**

Adrenal function was measured by the determination of 24-hour urinary 17-hydroxy-corticosteroids in 421 patients. Three hundred and ninety of 400 determinations of urinary 17-hydroxy-corticosteroids fell within normal range. No significant variations from pretreatment values occurred in percentages of elevations or decreases outside normal limits. Although within normal range, a trend toward lower values of urinary 17-hydroxy-corticosteroids was noted in most cases as duration of treatment was lengthened. In a special study of OVRAL® with regard to its effect on the response of the pituitary-adrenal axis to ACTH stimulation, (6 patients) there was no change from pretreatment response. With regard to metapyrone stimulation (6 patients) as measured by excretion of urinary 17-hydroxy-corticosteroids, the results revealed a lessened response than elicited prior to therapy. As with other oral contraceptives, this effect is generally believed to be due to an enhancement of the binding power of transcortin for adrenal cortical hormones after their secretion by the adrenal gland mediated through the estrogenic component of OVRAL®.

**Glucose Tolerance**

Results of glucose tolerance tests performed during controlled clinical trials on 21 control patients and 37 OVRAL® patients both prior and during treatment for short duration indicate no effect on carbohydrate tolerance while taking OVRAL®.

## **Hematology**

There were no significant variations from pretreatment determinations in the evaluation of routine hematology. Hemoglobin or hematocrit was determined in 8,462 patients; white cell counts were performed in 8,742 patients.

## **Cytology and Histology**

Cervical Papanicolaou smears were obtained from patients prior to and during treatment with OVRAL®. In 7 of 8 studies, 48 of 6,453 pretreatment smears (0.7%) and 47 of 9,287 treatment smears (0.5%) were abnormal (Class III, IV or V).

In one study, 45 of 1,290 pretreatment smears (3.5%) were classified as abnormal; of 1,598 post-treatment smears 61 (3.8%) were abnormal. In the remaining studies 47 of 5,992 (0.8%) represented pretreatment abnormal smears and 26 of 5,105 (0.5%) represented abnormal post-treatment smears. Cytology slide-reading differences and differences in population characteristics in the one aforementioned may have contributed to the higher percentage of both pretreatment and treatment abnormalities.

Pretreatment incidence, on cervical biopsy, of carcinoma in situ or carcinoma of the cervix was 3.1 per 1,000 (21 patients) as compared to an incidence of carcinoma in situ of the cervix, first diagnosed after six or more cycles on OVRAL®, of 3.7 per 1,000 (16 patients). Over 11,067 patients completed six or more cycles of therapy with OVRAL® and were included in the above calculations.

## PHARMACOLOGY

### Animal

Norgestrel is a racemate, composed of equal parts of d- and l-enantiomers. The d-enantiomer accounts for all biological activity.

Intensive biological investigations have been carried out with norgestrel alone and in combination with ethinyl estradiol in rats, mice, rabbits, dogs and monkeys.

In tests for progestational alteration of the endometrium of rabbits, norgestrel by the subcutaneous route proved to be about nine times more active than progesterone and about one hundred times more active than norethisterone by oral and subcutaneous routes. In contrast to norethisterone, which is inactive, norgestrel will maintain pregnancy in spayed laboratory rats and produce endometrial gland development in rabbits when administered directly into the uterine lumen. In a broad series of biological tests, its activities are similar to those of progesterone. Although certain androgenic effects typical of many relatives of 19-nortestosterone are evident at high doses, norgestrel is devoid of such effects at usual clinical doses, and the separation of progestational from androgenic effects for norgestrel is greater than for related compounds. Norgestrel is not estrogenic, nor is it apparently converted in vivo to estrogen; it is an exceedingly potent estrogen antagonist. When combined with ethinyl estradiol, norgestrel tends to ameliorate the effects of the estrogen, while the estrogen will modify the effects of the progestin. In rats, suppression of fertility with norgestrel/ethinyl estradiol combinations is followed by recovery of normal fertility and fecundity.

Additional experiments in laboratory animals were directed toward evaluating the endocrine effects and safety of the norgestrel and ethinyl estradiol formulation at dose levels approximating those employed clinically (on a milligram per kilogram basis). Metrotropic effects (uterine glandular development and growth) were most clearly demonstrated. Blockade of pituitary gonadotrophins can be produced by the estrogenic component alone at the clinical dose range; this pituitary effect does not appear to be modified by addition of the progestin.

The following properties, observed with high doses of norgestrel or norgestrel/ethinyl estradiol combinations, were absent at doses approximating the clinical range: pregnancy maintenance in spayed female rats; parturition delay in pregnant rats; estrogenic changes in mouse vaginal cytology; anti-estrogenic effect in mouse uterine growth or vaginal smear tests; androgenic, myotrophic or fetal masculinizing effects in rats; claudogenic (anti-nidatory) effects in rats; thymolymphatic involution in mice; mineralocorticoid effects in rats and dogs and anti-mineralocorticoid effects in rats. No glucocorticoid (rat liver glycogen) or anti-inflammatory (Selye pouch, TBR-arthritis or granuloma pellet tests) effects have been seen at any dose.

## **Human**

Progestins can have, in addition to progestational activity, estrogenic, anti-estrogenic and androgenic activity. When combined with estrogen, the progestin will markedly affect the overall biological activity by producing a synergistic summative or diminutional effect on activity. Comparisons of progestin potency are not considered scientifically valid because the effects of one progestin cannot be directly compared with those of another.<sup>15</sup>

A study of serum luteinizing hormone (LH), follicle stimulating hormone (FSH), progesterone and  $17\beta$ -estradiol in patients taking other low-dose oral contraceptives indicated reduction or abolition of the mid-cycle ovulatory peak and post-ovulatory levels commonly associated with these hormones and gonadotrophins respectively.

Endometrial biopsies taken during the course of OVRAL® therapy reveal a histological sequence in the menstrual cycle of early glandular epithelial stimulation followed by later inhibition after the first half of the menstrual cycle. During the last days of the treatment period, the endometrium presents an irregular appearance with small or medium-size glands. In about one-third of the specimens there are small plaques of predecidual reaction either peri-glandular or situated below the superficial epithelium. Stromal effects are minimal although occasional stromal edema is observed. A true secretory endometrium is seen in only 3.9% of the biopsies taken from patients on OVRAL®.

Results of 24-hour urinary pregnanediol determinations made in patients taking OVRAL® reveal anovulatory levels in the second half of the cycles in most instances (95.8%).

Cervical mucus specimens were examined at mid-cycle (days 11-16) in patients taking OVRAL® to determine its effect on the ferning phenomenon and spinnbarkeit. Sixteen examinations of seventeen (94.1%) revealed atypical to absent ferning and decreased spinnbarkeit, indicative of poor conditions for sperm penetration and migration.

A human study of the metabolism of  $^{14}\text{C}$ -labelled norgestrel, the progestin component of OVRAL®, revealed that most of the urinary excretion of norgestrel occurred on the first day. There was no difference in the rate of excretion of norgestrel whether administered orally or intravenously. The amount of radioactivity in plasma fell rapidly within the first few hours and at the end of two days only small amounts were present. The foregoing and other studies with  $^{14}\text{C}$ -labelled and unlabelled norgestrel have shown that saturation of the 4,5-double bond with and without concomitant reduction of the 3-carbonyl to a 3-hydroxyl group are important reactions during metabolism.

## **TOXICOLOGY**

### **Acute Toxicity**

Norgestrel alone, ethinyl estradiol alone and the two agents combined in a 10:1 ratio were given as single oral doses to rats, mice and dogs. LD<sub>50</sub> values for norgestrel alone and in combination were greater than 5,000 mg/kg in all species tested. The values for ethinyl estradiol were 2,952 (rat), 1,737 (mouse) and greater than 2,500 (dog) mg/kg.

The value for the combination exceeds 500,000 times the human oral dose of OVRAL®.

### **Subacute Toxicity**

In subacute toxicity trials in rats, ethinyl estradiol was fed at doses which approximated up to 8 mg/kg and norgestrel was fed at doses which approximated up to 200 mg/kg. Studies of a 10:1 ratio of norgestrel and ethinyl estradiol utilized doses which approximated up to 100 and 10 mg/kg, respectively. This last study represents a dose approximately 10,000 times the equivalent human oral dose of OVRAL®.

Since estrogens are known to enhance a reduction in both food consumption and growth rate in rodents, it was not unexpected that studies involving high doses of ethinyl estradiol either alone or in combination with norgestrel exhibited such findings. Studies of norgestrel alone at high doses demonstrated a similar but less marked reduction of food consumption and growth rate.

There were increases in the ratio of organ weight to body weight for the pituitary, heart, lungs, kidneys, spleen, pancreas, thyroid, brain and uterus. A decrease in the organ weight to body weight ratio was found for the seminal vesicles, ventral prostate, testes and ovaries. With the exception of the expected endocrine target organ effects, any interpretation of organ weight changes must consider the compounding influence of the substantial body weight changes cited above.

In subacute toxicity trials in dogs, ethinyl estradiol was administered at doses up to 1 mg/kg and norgestrel at doses up to 50 mg/kg. Studies of a 10:1 ratio of norgestrel and ethinyl estradiol combined utilized doses up to 10 and 1 mg/kg, respectively. This last study represents a dose in excess of 1,000 times the equivalent human dose of OVRAL®. At these dosage levels, there was a trend downward in hematocrits and hemoglobins. These changes were small and are not considered of biological importance. A similar interpretation was given to essentially incidental findings in assays of blood and urine chemistry. These changes were not seen at dosage levels approximating 100 times the human dose and lower.

## **Chronic Toxicity**

### **(Norgestrel and Ethinyl Estradiol)**

Long-term toxicity studies were conducted in rats and dogs for periods of up to 30 months. The dosage levels utilized approximated 700 times (rats) and 100 times (dogs) the usual human dose of OVRAL®. The components of OVRAL® were also studied individually in both species at a majority of the dosage levels used in the combination program.

Patchy, transient hair loss was observed in a few controls and occurred in the drug treatment group almost exclusively in animals treated with ethinyl estradiol or with ethinyl estradiol + norgestrel.

At doses of 35-50 times the human dose and above, a dose and time related incidence of lenticular opacities was seen in rats receiving ethinyl estradiol and ethinyl estradiol + norgestrel. The opacities are considered due to the ethinyl estradiol component and may be species specific since they were not seen in dogs.

In rats given doses of higher than 100 times the clinical dose of either ethinyl estradiol alone or in combination with norgestrel, there was a significant increase in the incidence of malignant mammary tumours. The data on norgestrel alone indicate that this material did not increase the incidence of mammary tumours in the rat. The overall results are similar to those cited in the literature for other estrogens. The meaning of these data is obscure since such effects have not been noted in human clinical use. Superficial mammary masses of varying sizes were seen to develop in treated rats as well as controls. Histopathological examination of the wall and content of these masses and clinical analysis of their content indicate that these masses are "milk cysts", possibly aggravated by continued secretion of acinar tissue despite obstruction of mammary ducts. There was no evidence of pre-neoplastic process or of benign or malignant neoplasia. In studies terminated by 9-12 months, there was a precocious appearance of masses in groups receiving ethinyl estradiol at 400-500 times the human use level of OVRAL®, irrespective of the level of norgestrel present. Norgestrel alone at over 700 times the human dose may have suppressed the spontaneous appearance of masses, but there was no evidence that norgestrel exerted a protective effect in any of the combinations tested.

In dogs, ongoing mammary gland studies ran for 7 years and were completed in November 1974. In monkeys, ongoing mammary gland studies ran for 10 years and were completed in December 1977.

Changes in organ weights observed after chronic studies were similar to those reported after shorter term tests and were due in part to reductions in food consumption and body weight.

Other findings related to treatment include cornification and cystic hyperplasia of the vaginal mucosa and exocervix, as well as cystic dilation and squamous hyperplasia and metaplasia of endometrial glands as expected. Similarly, endometritis and myometritis with pyometra were observed in dogs and endometritis with abscess formation was seen in rats; these effects were not noted at levels approaching the clinical dose and were most severe at 100 times (dogs) and 700 times (rats) the human dose. Epiphora with slight eversion of the lower eyelid, and mild hyperplasia of the gallbladder mucosa were seen in some dogs receiving norgestrel; and a brown pigment in the epithelium of the kidney tubules was seen in rats receiving ethinyl estradiol.

#### **(Norgestrel Alone)**

Studies were conducted in the mouse, the rat, the dog and the monkey. Mice were administered norgestrel at levels of up to 0.0014% in their diet for approximately 80 weeks. The histopathology reports showed that this level of dosing appeared quite innocuous and tumour incidence was not significant in relation to drug treatment at any dose level. When norgestrel was administered to rats in the diet at levels of up to 0.1% over 80 weeks, growth rate and food consumption were depressed in a dose-related manner. Small differences in hematology data from controls were well within

normal limits. Superficial mammary masses were seen to develop in treated as well as control animals. Histopathological examination of the wall and content of these masses and chemical analysis of their contents indicate that these masses are "milk cysts", possibly aggravated by continued secretion of acinar tissue despite obstruction of mammary ducts. There was no evidence of pre-neoplastic process or of benign or malignant neoplasia. Histological changes seen in female rats following administration of norgestrel alone were those to be expected from a progestational agent.

Chronic studies in dogs have been completed using continuous dosing of up to 20 mg/kg for 52 weeks and 0.2 mg/kg for 102 weeks. An ongoing lifetime study at 0.25 mg/kg given cyclically has been undertaken and the study is now completed at 84 months. At the end of 84 months (ninety-two cycles) no findings giving rise to concern were reported. A 7-year report of a chronic oral study in beagle dogs receiving norgestrel continuously in doses up to 37.5 mg/kg daily indicated no untoward changes in general pharmacology, blood chemistry, urinary steroids, hematology and hemostatic function have occurred in comparison to control animals. At 84 months, ophthalmoscopy showed macular eye changes for 5 control dogs and 16 treated dogs. During the study, one or more nodules were noted in the mammary or contiguous tissues of 6 control dogs and 11 treated dogs (5 dogs at the 3 mg/kg/day, 3 dogs at the 15 mg/kg/day and 3 dogs at the 37.5 mg/kg/day dosage levels).

In chronic studies in the female Rhesus monkey, norgestrel was dosed on a cyclic basis up to a multiple of 50 times the daily human dose. No changes related to the drug have been noted in the observation, hematology, biochemical studies, diabetogenic studies and urinary steroid excretion.

Cytological examination after 112 months of treatment revealed no evidence of vaginal neoplasia and palpation of mammae revealed no untoward findings. No differences believed to be related to treatment were seen between control and treated monkeys. A long-term oral study in female Rhesus monkeys in which norgestrel was administered continuously at dosage levels up to 75 mg/kg daily has been completed at 120 months. No changes considered to be related to the drug were seen in hematology, biochemistry, clotting studies or urinary steroids. At 120 months, fundic alterations (changes in the macula and/or fovea) were noted for 0 control monkeys and 7 treated monkeys (2 monkeys at the 3 mg/kg/day, 3 monkeys at the 15 mg/kg/day and 2 monkeys at the 75 mg/kg/day dosage levels). In a similar previous study, 8 monkeys in the control group had fundic alterations. One or more nodules were present in the mammary or contiguous tissues of 1 control monkey and 4 treated monkeys (1 monkey at the 3 mg/kg/day, 2 monkeys at the 15 mg/kg/day and 1 monkey at the 75 mg/kg/day dosage levels) throughout the study.

### **Reproduction and Teratology**

At doses in the clinical range, norgestrel, ethinyl estradiol and their combinations have no demonstrable effects on pregnant rats, their pregnancies, their offspring or the reproductive potential of the young.

Also at doses approximating the clinical range, norgestrel and/or ethinyl estradiol have no observable effects on lactating rats, the lactation process or the nursing young.

At doses in the clinical range and above, a small dose-related increase in the number of abnormal fetuses is observed in mice treated during pregnancy with norgestrel/ethinyl estradiol combinations

in a ratio of 5:1. Abnormalities include open eye, cleft palate, exencephaly and umbilical hernia.

Rabbits treated during pregnancy with doses of norgestrel and ethinyl estradiol in the clinical range and above, failed to demonstrate any teratogenic potential for the drug.

**REFERENCES**

1. Andelman MB, Zackler J, Walters JE. A low-dosage contraceptive in public health clinics. *J Reprod Fertil.* 1968; 5:117-124.
2. Drugs taken with oral contraceptives. *Br Med J.* 1967; 1:287.
3. Fotherby K. A metabolic assessment of different oral contraceptives. *J Obstet Gynecol.* 1983; 3, Suppl. 2:S77-S82.
4. Francis WG, Dalzeil D. Accidental ingestion of oral contraceptives by children. *Can Med Assoc J.* 1965; 92:191.
5. Korba VD, Heil CG. Eight years of fertility control with norgestrel-ethinyl estradiol (Ovral®): an updated clinical review. *Fertil Steril.* 1975; 26(10):973-981.
6. Laurie RE, Lewis ET. Fertility control with Ovral®: a clinical review. *J Reprod Fertil.* 1968; 5, Suppl.:95-107.
7. Littleton P, Fotherby K, Wilson G. Metabolism of norgestrel in humans. *Biochem J.* 1967; 103:14-15.
8. O'Roark HC, Lock FR, Smith Foushee JH, Burt RL. Preliminary clinical study of WY-3707 with ethinyl estradiol as an oral contraceptive. *Int J Fertil.* 1966; 11(4):405-411.
9. Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies. *Am J Obstet Gynecol.* 1985; 152(6):729-798.
10. Report on oral contraceptives, 1985. By: The Special Advisory Committee On Reproductive Physiology. To: The Health Protection Branch, Health and Welfare, Canada. Published by the authority of The Honorable Jake Epp, Minister of National Health and Welfare.

11. Rozenbaum H. Relationships between chemical structure and biological properties of progestogens. *Am J Obstet Gynecol.* 1982; 142(6), Part 2:719-724.
12. Sturtevant FM. Breast cancer and oral contraceptives. (Correspondence). *Lancet.* November 12, 1983; 1145.
13. Sturtevant FM. Breast cancer and oral contraceptives: critique of the proposition that high potency progestogen products confer excess risk. *Biomed Pharmacother.* 1984; 38:371-379.
14. The Centres for Disease Control, Cancer and Steroid Hormone Study. Long-term oral contraceptive use and the risk of breast cancer. *JAMA.* 1983; 249:1591-1595.
15. Toxicity of oral contraceptives. *Br Med J.* 1967; 1:36.